HK1041879A1 - 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents - Google Patents

4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents

Info

Publication number
HK1041879A1
HK1041879A1 HK02103436A HK02103436A HK1041879A1 HK 1041879 A1 HK1041879 A1 HK 1041879A1 HK 02103436 A HK02103436 A HK 02103436A HK 02103436 A HK02103436 A HK 02103436A HK 1041879 A1 HK1041879 A1 HK 1041879A1
Authority
HK
Hong Kong
Prior art keywords
antiviral agents
quinolinecarboxamides
dihydro
oxo
substituted
Prior art date
Application number
HK02103436A
Other languages
English (en)
Inventor
Steven Ronald Turner
Joseph Walter Strohbach
Suvit Thaisrivongs
Valerie A Vaillancourt
Mark E Schnute
Allen Scott
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HK1041879A1 publication Critical patent/HK1041879A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
HK02103436A 1999-01-08 2002-05-07 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents HK1041879A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11511399P 1999-01-08 1999-01-08
US13839099P 1999-06-09 1999-06-09
US14061499P 1999-06-23 1999-06-23
PCT/US1999/027959 WO2000040563A1 (en) 1999-01-08 1999-12-22 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents

Publications (1)

Publication Number Publication Date
HK1041879A1 true HK1041879A1 (en) 2002-07-26

Family

ID=27381602

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103436A HK1041879A1 (en) 1999-01-08 2002-05-07 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents

Country Status (28)

Country Link
US (1) US6248736B1 (xx)
EP (1) EP1140851B1 (xx)
JP (1) JP2002534417A (xx)
KR (1) KR20010101428A (xx)
CN (1) CN1132818C (xx)
AT (1) ATE275134T1 (xx)
AU (1) AU2158300A (xx)
BR (1) BR9916781A (xx)
CA (1) CA2353634A1 (xx)
CO (1) CO5150150A1 (xx)
CZ (1) CZ20012458A3 (xx)
DE (1) DE69919897T2 (xx)
EA (1) EA004043B1 (xx)
ES (1) ES2228162T3 (xx)
HK (1) HK1041879A1 (xx)
HU (1) HUP0105142A3 (xx)
ID (1) ID29452A (xx)
IL (1) IL144170A0 (xx)
MY (1) MY118904A (xx)
NO (1) NO320396B1 (xx)
NZ (1) NZ512823A (xx)
PE (1) PE20001337A1 (xx)
PL (1) PL348769A1 (xx)
PT (1) PT1140851E (xx)
SK (1) SK8312001A3 (xx)
TR (1) TR200101893T2 (xx)
TW (1) TW593281B (xx)
WO (1) WO2000040563A1 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP2004520424A (ja) 2001-03-01 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての置換型キノリンカルボキサミド
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
AR038294A1 (es) 2002-01-14 2005-01-12 Upjohn Co Oxotieno(3,2-b)piridincarboxamidas como agentes antivirales
AR038117A1 (es) 2002-01-14 2004-12-29 Upjohn Co Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida
AU2003262947A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
WO2004019933A1 (en) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
TR200401663T1 (tr) * 2002-11-20 2005-04-21 Japan Tobacco Inc. 4-oksokuinolin bileşiği ve bunun HIV integraz inhibitörü olarak kullanımı.
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
KR20060041254A (ko) 2003-07-24 2006-05-11 아스텔라스세이야쿠 가부시키가이샤 퀴놀론 유도체 또는 그의 염
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP3287130A1 (en) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
PT2489659T (pt) 2004-06-24 2018-03-07 Vertex Pharma Moduladores de transportadores de cassete de ligação a atp
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
BRPI0620960A2 (pt) 2005-12-28 2011-11-29 Vertex Pharmaceuticals Incorporated formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida
EP2452682A1 (en) * 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
MX2008011457A (es) * 2006-03-06 2008-09-24 Japan Tobacco Inc Metodo para producir un compuesto de 4-oxoquinolina.
DE102008036099B4 (de) 2008-08-04 2014-02-13 Steag Power Saar Gmbh Entstickungsanlage
KR101955863B1 (ko) 2009-03-20 2019-03-07 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
NZ604745A (en) * 2010-08-27 2015-01-30 Gruenenthal Chemie Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
SI2909192T1 (sl) 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Metilensko vezani kinolinilni modulatorji za ROR-gama-t
MX2015004784A (es) 2012-10-16 2015-08-14 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t.
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
CA3112326A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
CN114667285A (zh) 2019-09-26 2022-06-24 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593810B1 (fr) * 1986-01-24 1988-04-22 Sanofi Sa Derives de la quinoleine, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
WO1992004328A1 (en) * 1990-09-07 1992-03-19 Schering Corporation Antiviral compounds and antihypertensive compounds
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
EP0531578B1 (en) 1991-09-10 1995-12-20 Agfa-Gevaert N.V. Thermally transferable fluorescent compounds
PT841929E (pt) * 1995-08-02 2003-09-30 Darwin Discovery Ltd Quinolonas e sua utilizacao terapeutica
WO1997014682A1 (en) 1995-10-19 1997-04-24 Takeda Chemical Industries, Ltd. Quinoline derivatives as gnrh antagonists
ES2270475T3 (es) 1996-11-27 2007-04-01 Bristol-Myers Squibb Pharma Company Nuevos antagonistas de receptores de integrina.
BR9814323A (pt) 1997-12-22 2004-06-29 Upjohn Co 4-hidroxiquinolina-3-carboxamidas e hidrazidas como agentes antiviróticos

Also Published As

Publication number Publication date
WO2000040563A1 (en) 2000-07-13
NZ512823A (en) 2003-10-31
PL348769A1 (en) 2002-06-17
DE69919897D1 (en) 2004-10-07
CZ20012458A3 (cs) 2001-12-12
ES2228162T3 (es) 2005-04-01
EA200100755A1 (ru) 2001-12-24
CN1332729A (zh) 2002-01-23
ATE275134T1 (de) 2004-09-15
CO5150150A1 (es) 2002-04-29
NO20013379D0 (no) 2001-07-06
TW593281B (en) 2004-06-21
TR200101893T2 (tr) 2001-11-21
SK8312001A3 (en) 2001-12-03
ID29452A (id) 2001-08-30
BR9916781A (pt) 2001-12-04
EP1140851A1 (en) 2001-10-10
PT1140851E (pt) 2004-12-31
EA004043B1 (ru) 2003-12-25
HUP0105142A3 (en) 2002-05-28
DE69919897T2 (de) 2005-09-08
IL144170A0 (en) 2002-05-23
AU2158300A (en) 2000-07-24
NO320396B1 (no) 2005-11-28
JP2002534417A (ja) 2002-10-15
PE20001337A1 (es) 2000-11-23
CA2353634A1 (en) 2000-07-13
EP1140851B1 (en) 2004-09-01
CN1132818C (zh) 2003-12-31
KR20010101428A (ko) 2001-11-14
HUP0105142A2 (hu) 2002-04-29
US6248736B1 (en) 2001-06-19
MY118904A (en) 2005-02-28
NO20013379L (no) 2001-07-06

Similar Documents

Publication Publication Date Title
HK1041879A1 (en) 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
HK1036802A1 (en) Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
GB2248616B (en) Piperazine derivatives
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
ES2065994T3 (es) Beta-dicetonas substituidas.
TW427993B (en) New cephem compounds
ATE197297T1 (de) 3-oxo-1,4-benzothiazin-derivate
DE69217148D1 (de) Isoxazole derivate als lichtschutzmittel
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20071222